Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors. A 24-week Open-label, Proof-of-concept Pilot Clinical Trial.

Trial Profile

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors. A 24-week Open-label, Proof-of-concept Pilot Clinical Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Raltegravir (Primary) ; Darunavir; Lopinavir/ritonavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RIPIM
  • Most Recent Events

    • 04 Apr 2018 Results assessing the impact of intensification on low level viral replication, viral reservoirs, cellular immune activation and soluble markers of inflammation published in the Journal of Antimicrobial Chemotherapy
    • 10 Jun 2017 Biomarkers information updated
    • 27 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top